Brokerages expect that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will report earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.18). Iovance Biotherapeutics posted earnings per share of ($0.26) during the same quarter last year, which would indicate a negative year-over-year growth rate of 11.5%. The firm is expected to announce its next earnings results on Thursday, May 9th.

On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.22) per share for the current financial year, with EPS estimates ranging from ($1.47) to ($0.72). For the next fiscal year, analysts expect that the business will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.69) to ($0.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that cover Iovance Biotherapeutics.

IOVA has been the subject of several recent research reports. Oppenheimer set a $25.00 target price on Iovance Biotherapeutics and gave the company a “buy” rating in a report on Friday, January 11th. B. Riley initiated coverage on Iovance Biotherapeutics in a report on Monday, December 31st. They set a “buy” rating and a $24.00 target price for the company. Robert W. Baird initiated coverage on Iovance Biotherapeutics in a report on Wednesday, February 6th. They set an “outperform” rating and a $29.00 target price for the company. BidaskClub raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Iovance Biotherapeutics in a report on Tuesday, April 2nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.86.

Shares of NASDAQ:IOVA traded down $0.06 during trading on Tuesday, hitting $10.99. 1,226,235 shares of the company traded hands, compared to its average volume of 1,034,656. The firm has a market capitalization of $1.36 billion, a PE ratio of -8.65 and a beta of 1.91. Iovance Biotherapeutics has a one year low of $7.26 and a one year high of $18.25.

A number of hedge funds have recently modified their holdings of the stock. Advisor Group Inc. increased its stake in shares of Iovance Biotherapeutics by 58.6% in the fourth quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 3,000 shares during the last quarter. Kalos Management Inc. acquired a new position in Iovance Biotherapeutics during the fourth quarter worth $93,000. Virtu Financial LLC acquired a new position in Iovance Biotherapeutics during the first quarter worth $99,000. Great West Life Assurance Co. Can increased its position in Iovance Biotherapeutics by 67.4% during the fourth quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock worth $124,000 after buying an additional 5,853 shares during the last quarter. Finally, Amalgamated Bank acquired a new position in Iovance Biotherapeutics during the fourth quarter worth $130,000. 95.92% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: Blue-Chip Stocks

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.